{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T12:00:20Z","timestamp":1779105620135,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"JSPS KAKENHI","award":["23K08657"],"award-info":[{"award-number":["23K08657"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"DOI":"10.1007\/s13577-024-01157-9","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T13:04:12Z","timestamp":1733231052000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Establishment and characterization of the novel myxofibrosarcoma cell line, SMU-MFS"],"prefix":"10.1007","volume":"38","author":[{"given":"Naoya","family":"Nakahashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2512-2795","authenticated-orcid":false,"given":"Makoto","family":"Emori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohichi","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutaka","family":"Murahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Murase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohide","family":"Tsukahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Takasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kousuke","family":"Iba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Teramoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Osanai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"key":"1157_CR1","first-page":"124","volume-title":"Myxofibrosarcoma. WHO classification of tumours of soft tissue and bone","author":"HYMT Huang","year":"2020","unstructured":"Huang HYMT, Shibata T. Myxofibrosarcoma. WHO classification of tumours of soft tissue and bone. Lyon: IARC Press; 2020. p. 124\u20136."},{"key":"1157_CR2","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1245\/s10434-010-1341-4","volume":"18","author":"R Sanfilippo","year":"2011","unstructured":"Sanfilippo R, Miceli R, Grosso F, et al. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol. 2011;18:720\u20135.","journal-title":"Ann Surg Oncol"},{"key":"1157_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/jso.23708","volume":"110","author":"S Iwata","year":"2014","unstructured":"Iwata S, Yonemoto T, Araki A, et al. Impact of infiltrative growth on the outcome of patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma. J Surg Oncol. 2014;110:707\u201311.","journal-title":"J Surg Oncol"},{"key":"1157_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/830879","volume":"2012","author":"V Dewan","year":"2012","unstructured":"Dewan V, Darbyshire A, Sumathi V, Jeys L, Grimer R. Prognostic and survival factors in myxofibrosarcomas. Sarcoma. 2012;2012: 830879.","journal-title":"Sarcoma"},{"key":"1157_CR5","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1245\/s10434-015-5063-5","volume":"23","author":"AY Lee","year":"2016","unstructured":"Lee AY, Agaram NP, Qin LX, et al. Optimal percent myxoid component to predict outcome in high-grade myxofibrosarcoma and undifferentiated pleomorphic sarcoma. Ann Surg Oncol. 2016;23:818\u201325.","journal-title":"Ann Surg Oncol"},{"key":"1157_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1245\/s10434-012-2572-3","volume":"20","author":"NJ Look Hong","year":"2013","unstructured":"Look Hong NJ, Hornicek FJ, Raskin KA, et al. Prognostic factors and outcomes of patients with myxofibrosarcoma. Ann Surg Oncol. 2013;20:80\u20136.","journal-title":"Ann Surg Oncol"},{"key":"1157_CR7","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/cncr.26296","volume":"118","author":"RW Mutter","year":"2012","unstructured":"Mutter RW, Singer S, Zhang Z, Brennan MF, Alektiar KM. The enigma of myxofibrosarcoma of the extremity. Cancer. 2012;118:518\u201327.","journal-title":"Cancer"},{"key":"1157_CR8","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s13577-023-00944-0","volume":"36","author":"M Emori","year":"2023","unstructured":"Emori M, Nakahashi N, Takasawa A, et al. Establishment and characterization of a novel dedifferentiated chondrosarcoma cell line, SMU-DDCS, harboring an IDH1 mutation. Hum Cell. 2023;36:2195\u2013203.","journal-title":"Hum Cell"},{"key":"1157_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7171\/jbt.18-2902-002","volume":"29","author":"A Bairoch","year":"2018","unstructured":"Bairoch A. The cellosaurus, a cell-line knowledge resource. J Biomol Tech. 2018;29:25\u201338.","journal-title":"J Biomol Tech"},{"key":"1157_CR10","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.3390\/cancers15215132","volume":"15","author":"E Lucarelli","year":"2023","unstructured":"Lucarelli E, De Vita A, Bellotti C, et al. Modeling myxofibrosarcoma: where do we stand and what is missing? Cancers (Basel). 2023;15:5132.","journal-title":"Cancers (Basel)."},{"key":"1157_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/jcb.21073","volume":"100","author":"V Moneo","year":"2007","unstructured":"Moneo V, Serelde BG, Fominaya J, et al. Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J Cell Biochem. 2007;100:339\u201348.","journal-title":"J Cell Biochem"},{"key":"1157_CR12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/cells7110186","volume":"7","author":"G Miserocchi","year":"2018","unstructured":"Miserocchi G, De Vita A, Mercatali L, et al. Characterization and drug sensitivity of a new high-grade myxofibrosarcoma cell line. Cells. 2018;7:186.","journal-title":"Cells"},{"key":"1157_CR13","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1186\/s12885-023-11658-9","volume":"23","author":"AN Guerrieri","year":"2023","unstructured":"Guerrieri AN, Bellotti C, Penzo M, et al. A novel patient-derived immortalised cell line of myxofibrosarcoma: a tool for preclinical drugs testing and the generation of near-patient models. BMC Cancer. 2023;23:1194.","journal-title":"BMC Cancer"},{"key":"1157_CR14","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1186\/1471-2407-13-563","volume":"13","author":"B Lohberger","year":"2013","unstructured":"Lohberger B, Stuendl N, Wolf E, Liegl-Atzwanger B, Leithner A, Rinner B. The novel myxofibrosarcoma cell line MUG-Myx1 expresses a tumourigenic stem-like cell population with high aldehyde dehydrogenase 1 activity. BMC Cancer. 2013;13:563.","journal-title":"BMC Cancer"},{"key":"1157_CR15","doi-asserted-by":"publisher","first-page":"44700","DOI":"10.1038\/srep44700","volume":"7","author":"B Lohberger","year":"2017","unstructured":"Lohberger B, Stuendl N, Leithner A, et al. Establishment of a novel cellular model for myxofibrosarcoma heterogeneity. Sci Rep. 2017;7:44700.","journal-title":"Sci Rep"},{"key":"1157_CR16","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s13577-018-00233-1","volume":"32","author":"F Kito","year":"2019","unstructured":"Kito F, Oyama R, Sakumoto M, et al. Establishment and characterization of a novel cell line, NCC-MFS1-C1, derived from a patient with myxofibrosarcoma. Hum Cell. 2019;32:214\u201322.","journal-title":"Hum Cell"},{"key":"1157_CR17","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s13577-020-00420-z","volume":"34","author":"R Noguchi","year":"2021","unstructured":"Noguchi R, Yoshimatsu Y, Ono T, et al. Establishment and characterization of NCC-MFS2-C1: a novel patient-derived cancer cell line of myxofibrosarcoma. Hum Cell. 2021;34:246\u201353.","journal-title":"Hum Cell"},{"key":"1157_CR18","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1007\/s13577-021-00548-6","volume":"34","author":"R Tsuchiya","year":"2021","unstructured":"Tsuchiya R, Yoshimatsu Y, Noguchi R, et al. Establishment and characterization of NCC-MFS3-C1: a novel patient-derived cell line of myxofibrosarcoma. Hum Cell. 2021;34:1266\u201373.","journal-title":"Hum Cell"},{"key":"1157_CR19","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1007\/s13577-021-00589-x","volume":"34","author":"Y Yoshimatsu","year":"2021","unstructured":"Yoshimatsu Y, Noguchi R, Tsuchiya R, et al. Establishment and characterization of NCC-MFS4-C1: a novel patient-derived cell line of myxofibrosarcoma. Hum Cell. 2021;34:1911\u20138.","journal-title":"Hum Cell"},{"key":"1157_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/cells11020207","volume":"11","author":"R Tsuchiya","year":"2022","unstructured":"Tsuchiya R, Yoshimatsu Y, Noguchi R, et al. Establishment and characterization of NCC-MFS5-C1: a novel patient-derived cell line of myxofibrosarcoma. Cells. 2022;11:207.","journal-title":"Cells"},{"key":"1157_CR21","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s13577-022-00749-7","volume":"35","author":"Y Yoshimatsu","year":"2022","unstructured":"Yoshimatsu Y, Noguchi R, Sin Y, et al. Establishment and characterization of NCC-MFS6-C1: a novel patient-derived cell line of myxofibrosarcoma. Hum Cell. 2022;35:1993\u20132001.","journal-title":"Hum Cell"},{"key":"1157_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.cancergencyto.2005.02.003","volume":"161","author":"H Kawashima","year":"2005","unstructured":"Kawashima H, Ogose A, Gu W, et al. Establishment and characterization of a novel myxofibrosarcoma cell line. Cancer Genet Cytogenet. 2005;161:28\u201335.","journal-title":"Cancer Genet Cytogenet"},{"key":"1157_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1756-9966-28-44","volume":"28","author":"T Ariizumi","year":"2009","unstructured":"Ariizumi T, Ogose A, Kawashima H, Hotta T, Umezu H, Endo N. Multinucleation followed by an acytokinetic cell division in myxofibrosarcoma with giant cell proliferation. J Exp Clin Cancer Res. 2009;28:44.","journal-title":"J Exp Clin Cancer Res"},{"key":"1157_CR24","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/bjc.2016.259","volume":"115","author":"A Salawu","year":"2016","unstructured":"Salawu A, Fernando M, Hughes D, et al. Establishment and molecular characterisation of seven novel soft-tissue sarcoma cell lines. Br J Cancer. 2016;115:1058\u201368.","journal-title":"Br J Cancer"},{"key":"1157_CR25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/1097-0142(19920115)69:2<437::AID-CNCR2820690227>3.0.CO;2-U","volume":"69","author":"H Iwasaki","year":"1992","unstructured":"Iwasaki H, Isayama T, Ohjimi Y, et al. Malignant fibrous histiocytoma. A tumor of facultative histiocytes showing mesenchymal differentiation in cultured cell lines. Cancer. 1992;69:437\u201347.","journal-title":"Cancer"},{"key":"1157_CR26","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S0165-4608(96)00223-3","volume":"94","author":"AK Krause","year":"1997","unstructured":"Krause AK, Hinrichs SH, Orndal C, DeBoer J, Neff JR, Bridge JA. Characterization of a human myxoid malignant fibrous histiocytoma cell line, OH931. Cancer Genet Cytogenet. 1997;94:138\u201343.","journal-title":"Cancer Genet Cytogenet"},{"key":"1157_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0165-4608(00)00413-1","volume":"127","author":"Y Kiyozuka","year":"2001","unstructured":"Kiyozuka Y, Nakagawa H, Uemura Y, et al. Novel cell lines established from a human myxoid malignant fibrous histiocytoma arising in the uterus. Cancer Genet Cytogenet. 2001;127:7\u201315.","journal-title":"Cancer Genet Cytogenet"},{"key":"1157_CR28","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1158\/2159-8290.CD-15-1481","volume":"6","author":"T Okada","year":"2016","unstructured":"Okada T, Lee AY, Qin LX, et al. Integrin-\u03b110 Dependency Identifies RAC and RICTOR as therapeutic targets in high-grade myxofibrosarcoma. Cancer Discov. 2016;6:1148\u201365.","journal-title":"Cancer Discov"},{"key":"1157_CR29","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1158\/0008-5472.CAN-19-1269","volume":"80","author":"GZ Li","year":"2020","unstructured":"Li GZ, Okada T, Kim YM, et al. Rb and p53-Deficient Myxofibrosarcoma and undifferentiated pleomorphic sarcoma require Skp2 for survival. Cancer Res. 2020;80:2461\u201371.","journal-title":"Cancer Res"},{"key":"1157_CR30","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1177\/1758834017737472","volume":"9","author":"A De Vita","year":"2017","unstructured":"De Vita A, Recine F, Mercatali L, et al. Myxofibrosarcoma primary cultures: molecular and pharmacological profile. Ther Adv Med Oncol. 2017;9:755\u201367.","journal-title":"Ther Adv Med Oncol"},{"key":"1157_CR31","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1158\/1078-0432.CCR-19-2297","volume":"26","author":"MA Piano","year":"2020","unstructured":"Piano MA, Brunello A, Cappellesso R, et al. Periostin and Epithelial-Mesenchymal Transition Score as Novel Prognostic Markers for Leiomyosarcoma, Myxofibrosarcoma, and Undifferentiated Pleomorphic Sarcoma. Clin Cancer Res. 2020;26:2921\u201331.","journal-title":"Clin Cancer Res"},{"key":"1157_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2020.153262","volume":"76","author":"B Lohberger","year":"2020","unstructured":"Lohberger B, Bernhart E, Stuendl N, et al. Periplocin mediates TRAIL-induced apoptosis and cell cycle arrest in human myxofibrosarcoma cells via the ERK\/p38\/JNK pathway. Phytomedicine. 2020;76: 153262.","journal-title":"Phytomedicine"},{"key":"1157_CR33","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.cell.2013.08.003","volume":"154","author":"A Basu","year":"2013","unstructured":"Basu A, Bodycombe NE, Cheah JH, et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell. 2013;154:1151\u201361.","journal-title":"Cell"},{"key":"1157_CR34","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603\u20137.","journal-title":"Nature"},{"key":"1157_CR35","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang W, Soares J, Greninger P, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:D955\u201361.","journal-title":"Nucleic Acids Res"},{"key":"1157_CR36","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nrc1951","volume":"6","author":"RH Shoemaker","year":"2006","unstructured":"Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6:813\u201323.","journal-title":"Nat Rev Cancer"},{"key":"1157_CR37","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","volume":"15","author":"I Judson","year":"2014","unstructured":"Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15:415\u201323.","journal-title":"Lancet Oncol"},{"key":"1157_CR38","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/cncr.29961","volume":"122","author":"T Nakamura","year":"2016","unstructured":"Nakamura T, Matsumine A, Kawai A, et al. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: a Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer. 2016;122:1408\u201316.","journal-title":"Cancer"},{"key":"1157_CR39","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3332\/ecancer.2021.1281","volume":"15","author":"B Kataria","year":"2021","unstructured":"Kataria B, Sharma A, Biswas B, Bakhshi S, Pushpam D. Pazopanib in rare histologies of metastatic soft tissue sarcoma. Ecancermedicalscience. 2021;15:1281.","journal-title":"Ecancermedicalscience"},{"key":"1157_CR40","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1200\/JCO.2017.75.3467","volume":"36","author":"BC Widemann","year":"2018","unstructured":"Widemann BC, Italiano A. Biology and management of undifferentiated pleomorphic sarcoma, myxofibrosarcoma, and malignant peripheral nerve sheath tumors: state of the art and perspectives. J Clin Oncol: Off J Am Soc Clin Oncol. 2018;36:160\u20137.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"1157_CR41","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1038\/modpathol.2017.94","volume":"30","author":"E Heitzer","year":"2017","unstructured":"Heitzer E, Sunitsch S, Gilg MM, et al. Expanded molecular profiling of myxofibrosarcoma reveals potentially actionable targets. Mod Pathol. 2017;30:1698\u2013709.","journal-title":"Mod Pathol"},{"key":"1157_CR42","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/ng.619","volume":"42","author":"J Barretina","year":"2010","unstructured":"Barretina J, Taylor BS, Banerji S, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010;42:715\u201321.","journal-title":"Nat Genet"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-024-01157-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-024-01157-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-024-01157-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T09:21:22Z","timestamp":1736414482000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-024-01157-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["1157"],"URL":"https:\/\/doi.org\/10.1007\/s13577-024-01157-9","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]},"assertion":[{"value":"2 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of Sapporo Medical University (reference number 282\u2013156). Written informed consent was obtained from the patient in accordance with the guidelines of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"25"}}